tretazicar has been researched along with nad in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Friedlos, F; Knox, RJ | 1 |
| Abrahamson, JA; Biggs, PJ; Friedlos, F; Knox, RJ | 1 |
| Baer, J; Bagshawe, KD; Sunters, A | 1 |
| Friedlos, F; Jarman, M; Knox, RJ; Roberts, JJ | 1 |
| Anlezark, GM; Davies, LC; Friedlos, F; Goddard, P; Jarman, M; Knox, RJ; Melton, RG; Sherwood, RF | 1 |
| Helsby, NA; Tang, MH; Tingle, MD; Wilson, WR | 1 |
| Boddy, AV; Jamieson, D; Knox, RJ; Tung, AT | 1 |
| Anderson, JLR; Christofferson, AJ; Day, MA; Evans, A; Hyde, EI; Searle, PF; Vass, SO; White, SA | 1 |
8 other study(ies) available for tretazicar and nad
| Article | Year |
|---|---|
Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system.
Topics: Animals; Antineoplastic Agents; Aziridines; Biotransformation; Blood; Blood Coagulation; Cattle; Dihydrolipoamide Dehydrogenase; Horses; Humans; Hydrolysis; Lactates; NAD; NADP; Niacinamide; Oxidation-Reduction; Prodrugs; Tumor Cells, Cultured | 1992 |
Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity.
Topics: Antineoplastic Agents; Aziridines; DNA, Neoplasm; Drug Synergism; Humans; Intracellular Fluid; Kinetics; NAD; NAD(P)H Dehydrogenase (Quinone); Niacinamide; Pyridinium Compounds; Ribonucleosides; Stimulation, Chemical; Tumor Cells, Cultured | 1992 |
Cytotoxicity and activation of CB1954 in a human tumour cell line.
Topics: Animals; Antineoplastic Agents; Aziridines; Biotransformation; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; NAD; Nitroreductases; Prodrugs; Tumor Cells, Cultured | 1991 |
A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.
Topics: Animals; Antineoplastic Agents; Aziridines; Azirines; Carcinoma 256, Walker; Cell Survival; Cricetinae; Cross-Linking Reagents; DNA Damage; NAD; Nitroreductases; Oxidoreductases; Rats; Tumor Cells, Cultured | 1988 |
Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT).
Topics: Animals; Antibodies; Aziridines; Escherichia coli; Mice; NAD; Nitroreductases; Oxidation-Reduction; Prodrugs; Pyridinium Compounds; Ribonucleosides; Vitamin K | 1995 |
Aerobic 2- and 4-nitroreduction of CB 1954 by human liver.
Topics: Antineoplastic Agents; Aziridines; Carbon Monoxide; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Cytosol; Cytotoxins; Dicumarol; Escherichia coli; Humans; Hydroxylamines; Hypoxia; Liver; Mass Spectrometry; Microsomes, Liver; NAD; NADP; Nitroreductases; Prodrugs | 2005 |
Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor.
Topics: Alkylating Agents; Animals; Aziridines; Catalysis; Cell Line; Comet Assay; Electron Transport; Humans; Mitomycin; NAD; NAD(P)H Dehydrogenase (Quinone); Oxidation-Reduction; Quercetin; Quinone Reductases; Recombinant Proteins; Transfection | 2006 |
Structure and Dynamics of Three
Topics: Escherichia coli; Escherichia coli Proteins; Humans; NAD; Neoplasms; Nitroreductases; Oxidoreductases; Prodrugs | 2023 |